scholarly journals Paraganglioma of the thyroid gland: A case report

2014 ◽  
Vol 71 (9) ◽  
pp. 875-878 ◽  
Author(s):  
Aleksandar Filipovic ◽  
Ljiljana Vuckovic ◽  
Ljubica Pejakov
Keyword(s):  
Case Report ◽  
Thyroid Gland ◽  
Ct Scan ◽  
Neuroendocrine Tumor ◽  
Radionuclide Therapy ◽  
Neuron Specific Enolase ◽  
Peptide Receptor Radionuclide Therapy ◽  
Left Lobe ◽  
Whole Body ◽  
Peptide Receptor

Introduction. Thyroid paraganglioma is a very rare malignant neuroendocrine tumor. Immunohistochemical features of thyroid paraganglioma are helpful for the diagnosis. Case report. A 69-year-old female came to hospital with the presence of a growing thyroid nodule of the left lobe. Ultrasonic neck examination showed 5 cm hypoechoic nodule in the left thyroid lobe. Thyroid scintigraphy showed a big cold nodule in the left lobe. Computed tomography (CT) scan showed left lobe thyroid tumor with tracheal deviation on the right site. Extended total thyroidectomy was done. Intraoperative consultation with the pathologist confirmed thyroid cancer. The pathologist diagnosed thyroid paraganglioma on the base of immuohistochemical investigation. This thyroid paraganglioma was positive for neuron-specific enolase, chomogranin A, synaptophysin, and S-100 protein highlighted the sustentacular cells. Tumor cells were nega-tive for thyroglobulin, epithelial membrane antigen, cytokeratin, calcitonin, and carcinoembryonic. After the surgery the patient was treated with chemotherapy, peptide receptor radionuclide therapy, and permanent TSH suppressive therapy. The patient was followed with measurements of thyroid hormone and serum neuron-specific enolase, chromogranin A level, every 6 months. Gastroscopy, colonoscopy, chest and abdomen CT scan as well as further tests (chest x-ray, ultrasound of the neck, and whole body octreotide scintigraphy) were done. No primary neuroendocrine tumor in digestive sistem or in the chest was found. After more than 3 years the patient has no evidence of the recurrent disease. Conclusion. Radical resection of thyroid paraganglioma, followed by chemotherapy and peptide receptor radionuclide therapy, should be considered the treatment of choice in patients with thyroid gland paraganglioma.

scholarly journals Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 504
Author(s):  
Fiona Ohlendorf ◽  
Rudolf Werner ◽  
Christoph Henkenberens ◽  
Tobias Ross ◽  
Hans Christiansen ◽  
...  
Keyword(s):  
Treatment Response ◽  
Neuroendocrine Tumors ◽  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Tumor Burden ◽  
Inflammatory Biomarkers ◽  
Whole Body ◽  
Prognostic Impact ◽  
Peptide Receptor

Tumor microenvironment inflammation contributes to the proliferation and survival of malignant cells, angiogenesis, metastasis, subversion of adaptive immunity, and reduced treatment response. We aimed to evaluate the early predictive and prognostic significance of markers of systemic inflammation in patients receiving somatostatin-receptor targeted peptide receptor radionuclide therapy (PRRT). This retrospective observational cohort study included 33 patients with advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) treated with PRRT. Pretreatment blood-based inflammatory biomarkers, e.g., Creactive protein levels (CRP), white blood cell count (WBC), and absolute neutrophil count (ANC), were documented and inflammation indexes, e.g., neutrophil-lymphocyte ratio (NLR) and Platelet × CRP multiplier (PCM), were calculated. Tumor burden was determined using [68Ga]GaDOTATATE PET/CT before enrollment and every 2 cycles thereafter until progression. Therapy response was assessed using RECIST 1.1, including its volumetric modification. Inflammatory biomarkers and inflammatory indexes demonstrated marked heterogeneity among patients, and were significantly higher in non-responders (e.g., CRP (P < 0.001), ANC (P = 0.002), and PCM (P < 0.001)). Change in whole-body tumor burden after two cycles of PRRT was significantly associated with CRP (P = 0.0157) and NLR (P = 0.0040) in multivariate regression analysis. A cut-off of 2.5 mg/L for CRP (AUC = 0.84, P = 0.001) revealed a significant outcome difference between patients with adversely high vs. low CRP (median PFS 508 days vs. not yet reached (HR = 4.52; 95% CI, 1.27 to 16.18; P = 0.02)). Tumor-driven systemic inflammatory networks may be associated with treatment response, change in tumor burden, and prognosis in patients with GEPNETs receiving PRRT.

scholarly journals A Case of Primary Hepatic Neuroendocrine Tumor and Literature Review

2021 ◽  
pp. 90-97
Author(s):  
Pak Chiu Wong ◽  
Wong Hoi She ◽  
Ui Soon Khoo ◽  
Tan To Cheung
Keyword(s):  
Liver Resection ◽  
Neuroendocrine Tumor ◽  
Preoperative Diagnosis ◽  
Radionuclide Therapy ◽  
Tumor Recurrence ◽  
Peptide Receptor Radionuclide Therapy ◽  
Rare Tumor ◽  
Major Liver Resection ◽  
Peptide Receptor ◽  
Primary Hepatic Neuroendocrine Tumor

We report an unusual presentation of primary hepatic neuroendocrine tumor which was initially misdiagnosed as intrahepatic cholangiocarcinoma. The diagnosis was only revealed after a major liver resection by histopathology. With adjuvant lanreotide injection, the patient survived for more than 16 months after the operation without tumor recurrence. Diagnosis of this rare tumor has been a major challenge and we emphasize the importance of a preoperative diagnosis. Surgical resection remains the mainstay for curative treatment, while peptide receptor radionuclide therapy is an emerging treatment option which has provided promising results.

scholarly journals Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor

Oncotarget ◽  
2018 ◽  
Vol 9 (37) ◽  
pp. 24693-24706 ◽  
Author(s):  
Nupur K. Purohit ◽  
Rashmi G. Shah ◽  
Samuel Adant ◽  
Michael Hoepfner ◽  
Girish M. Shah ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Cells ◽  
Radionuclide Therapy ◽  
Parp Inhibitor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

Sa1152 TUMOR RESPONSE TO PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN A UNITED STATES-BASED NEUROENDOCRINE TUMOR COHORT

2020 ◽  
Vol 158 (6) ◽  
pp. S-292
Author(s):  
Sarit T. Kipnis ◽  
Matthew Hung ◽  
Jason Heckert ◽  
Bonita J. Bennett ◽  
Caroline Creamer ◽  
...  
Keyword(s):  
United States ◽  
Neuroendocrine Tumor ◽  
Radionuclide Therapy ◽  
Tumor Response ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor
Sign in / Sign up

Export Citation Format

Share Document